Citations

Clear

813 citation(s) found for "He, Helen".

Mutations in Fibrillin-1 Cause Congenital Scleroderma: Stiff Skin Syndrome
Loeys, Bart , Gerber, Elizabeth E. , Riegert‐Johnson, Douglas L. , Iqbal, Sarah , Whiteman, Pat, McConnell, Vivienne, Chillakuri, Chandramouli , Macaya, Daniela , Coucke, Paul , Paepe, Anne De , Judge, Daniel P. , Wigley, Fredrick M. , Mardon, Helen J., Handford, Penny A. , Keene, Douglas R. , Sakai, Lynn Y. , Dietz, Harry C. , Davis, Elise C. , Judge, Daniel P

Mayo Clinic

Science Translational Medicine | March 17, 2010 | Volume: 2 | Issue: 23 | Pages: No page available

10.1126/scitranslmed.3000488 | PMID 20375004 Get It

Stiff skin syndrome, an autosomal dominant congenital form of scleroderma, is caused by mutations in the domain of fibrillin-1 that mediates integrin binding.
Infants of Women with Polycystic Ovary Syndrome Have Lower Cord Blood Androstenedione and Estradiol Levels
Anderson, Helen, Fogel, Naomi, Grebe, Stefan K., Dunaif, Andrea , Singh, Ravinder J. , Taylor, Robert L.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 13, 2010 | Volume: 95 | Issue: 5 | Pages: 2180-2186

10.1210/jc.2009-2651 | PMID 20228162 Get It

Abstract Context: Prenatal androgen excess can cause a phenocopy of polycystic ovary syndrome (PCOS) in mammals. Retrospective studies have suggested that girls at risk for PCOS have low birth weight, and prospective studies have suggested an increased prevalence of small-for-gestational-age offspring in women with PCOS. Objective: The objective of the study was to determine whether infants of women with PCOS have reduced birth weight or increased intrauterine androgen levels. Design: This was a prospective case-control study. Participants: Thirty-nine PCOS and 31 control women and their infants participated in the study. Main Outcome Measures: Birth weight and mixed cord blood testosterone, androstenedione (A), dehydroepiandrosterone, 17-hydroxyprogesterone, estradiol (E2), and dihydrotestosterone levels were measured. Results: Mean birth weight did not differ, but there was a significant increase in the prevalence of large-for-gestational-age infants in the PCOS group. Cord blood E2 and A levels were lower (P < 0.05), but testosterone to E2 ratios did not differ in female PCOS compared with control offspring. There was no difference in E2 and A levels in the male PCOS and control offspring. There was no difference in 17-hydroxyprogesterone or other androgen levels in either male or female PCOS offspring compared with their respective control group. Conclusion: Infants of women with PCOS were more likely to be large for gestational age. Female offspring of affected women have lower cord blood A levels; other cord blood androgen levels do not differ compared with female control offspring. Cord blood E2 levels are also significantly decreased in PCOS, without any difference in the testosterone to E2 ratio, suggesting decreased fetal or placental production of steroids.
Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer
Ross, Helen J. , Blumenschein, George R. , Aisner, Joseph , Damjanov, Nevena , Dowlati, Afshin , Garst, Jennifer, Rigas, James R. , Smylie, Michael , Hassani, Habib, Allen, Kimberly E., Leopold, Lance, Zaks, Tal, Shepherd, Frances Alice

Mayo Clinic

Clinical Cancer Research | March 9, 2010 | Volume: 16 | Issue: 6 | Pages: 1938-1949

10.1158/1078-0432.ccr-08-3328 | PMID 20215545 Get It

Abstract Purpose: This randomized phase II study was initially designed to test the activity of two dose schedules of lapatinib (GW572016H), an oral, reversible, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2/neu; HER2), in chemotherapy-naive patients with non–small cell lung cancer (NSCLC); it was later amended to target patients with bronchioloalveolar carcinoma or no smoking history. Experimental Design: Patients with good performance status and recurrent or metastatic NSCLC were randomized to lapatinib (orally, 1,500 mg once daily or 500 mg twice daily) until progression or intolerance. Patients could have had a maximum of one prior systemic therapy (chemotherapy or biological therapy) for NSCLC. Safety and activity were assessed every 4 and 8 weeks, respectively. Tumors were analyzed for EGFR and HER2 mutations and/or amplifications. Results: Of 75 patients in the nontargeted population, 1 (1.3%) had partial response and 16 (21%) had stable disease of ≥24 weeks. No complete or partial responses were observed in 56 patients in the targeted population; 14 (25%) had stable disease of ≥24 weeks. No responses were seen in three patients with EGFR mutations and five with EGFR gene amplification. No mutations in HER2 were found. One of two patients with HER2 amplification had a 51% decrease in tumor size; however, this response was unconfirmed. The most common adverse events were grade 1 or 2 diarrhea, rash, fatigue, nausea, and anorexia. Adverse events were similar across dosing regimens. Conclusions: Lapatinib was well tolerated, with no notable difference in toxicity between treatment groups. Lapatinib monotherapy did not induce a significant number of tumor regressions in NSCLC. Further studies may be warranted to determine whether lapatinib is active in combination with other agents in the treatment of NSCLC. Clin Cancer Res; 16(6); 1938–49
Prevalence of low femoral bone density in older U.S. women from NHANES III
Looker, Anne C. , Johnston, C. Conrad, Wahner, Heinz W., Dunn, William L., Calvo, Mona S. , Harris, Tamara B., Heyse, Stephen P., Lindsay, Robert

Mayo Clinic

Journal of Bone and Mineral Research | February 3, 2010 | Volume: 10 | Issue: 5 | Pages: 796-802

10.1002/jbmr.5650100517 | PMID 7639115 Get It

Abstract Data on the number of U.S. women with low femoral bone mineral density (BMD) are currently available only from indirect estimates. We used dual-energy X-ray absorptiometry (DXA) measurements of femoral BMD from phase 1 of the third National Health and Nutrition Examination Survey (NHANES III, 1988–1991) to estimate prevalences of low femoral BMD in women ages 50 years and older using an approach proposed recently by an expert panel of the World Health Organization (WHO). Cutpoints for low BMD were derived from BMD data of 194 non-Hispanic white (NHW) women aged 20–29 years from the NHANES III dataset. The prevalence of older U.S. women with femoral osteopenia (BMD between 1 standard deviation [SD] and 2.5 SD below the mean of young NHW women) ranged from 34–50% in four different femur regions, which corresponds to ∼12–17 million women. The prevalence with osteoporosis (BMD >2.5 SD below the mean of young NHW women) ranged from 17–20%, or ∼6–7 million women. Prevalences were 1.3–2.4 times higher in NHW women than non-Hispanic black women (NHB), and 0.8–1.2 times higher in NHW versus Mexican American (MA) women. The estimated numbers of NHW, NHB, and MA women with osteopenia were 10–15 million, 800,000–1.2 million, and 300,000–400,000, respectively; corresponding figures for osteoporosis were 5–6 million, 200,000–300,000, and 100,000 respectively. Thus, the first data on BMD from a nationally representative sample of older women show a substantial number with low femoral BMD. The majority of these women are white, but the number of minority women with low BMD is not trivial.
Impact of Type 1 Diabetes and Insulin Treatment on Plasma Levels and Fractional Synthesis Rate of Retinol-Binding Protein 4
Jourdan, Marion, Jaleel, Abdul , Karakelides, Helen, Ford, G. C., Kahn, Barbara B. , Nair, K. Sreekumaran

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 3, 2009 | Volume: 94 | Issue: 12 | Pages: 5125-5130

10.1210/jc.2009-1331 | PMID 19850685 Get It

Consensus Statement on the Terminology and Classification of Central Neck Dissection for Thyroid Cancer
Carty, Sally E. , Cooper, David S. , Doherty, Gerard M. , Duh, Quan‐Yang , Kloos, Richard T. , Mandel, Susan J., Stack, Brendan C. , Steward, David L. , Terris, David J. , Thompson, Geoffrey B. , Tuttle, R. Michael , Udelsman, Robert, Randolph, Gregory William , Tufano, Ralph Patrick , Kloos, Richard T

Mayo Clinic

Thyroid | October 27, 2009 | Volume: 19 | Issue: 11 | Pages: 1153-1158

10.1089/thy.2009.0159 | PMID 19860578 Get It

Age, Obesity, and Sex Effects on Insulin Sensitivity and Skeletal Muscle Mitochondrial Function
Karakelides, Helen, Irving, Brian A. , Short, Kevin R. , O’Brien, Peter C. , Nair, K. Sreekumaran

Mayo Clinic

Diabetes | October 16, 2009 | Volume: 59 | Issue: 1 | Pages: 89-97

10.2337/db09-0591 | PMID 19833885 Get It

OBJECTIVE Reductions in insulin sensitivity in conjunction with muscle mitochondrial dysfunction have been reported to occur in many conditions including aging. The objective was to determine whether insulin resistance and mitochondrial dysfunction are directly related to chronological age or are related to age-related changes in body composition. RESEARCH DESIGN AND METHODS Twelve young lean, 12 young obese, 12 elderly lean, and 12 elderly obese sedentary adults were studied. Insulin sensitivity was measured by a hyperinsulinemic-euglycemic clamp, and skeletal muscle mitochondrial ATP production rates (MAPRs) were measured in freshly isolated mitochondria obtained from vastus lateralis biopsy samples using the luciferase reaction. RESULTS Obese participants, independent of age, had reduced insulin sensitivity based on lower rates of glucose infusion during a hyperinsulinemic-euglycemic clamp. In contrast, age had no independent effect on insulin sensitivity. However, the elderly participants had lower muscle MAPRs than the young participants, independent of obesity. Elderly participants also had higher levels inflammatory cytokines and total adiponectin. In addition, higher muscle MAPRs were also noted in men than in women, whereas glucose infusion rates were higher in women. CONCLUSIONS The results demonstrate that age-related reductions in insulin sensitivity are likely due to an age-related increase in adiposity rather than a consequence of advanced chronological age. The results also indicate that an age-related decrease in muscle mitochondrial function is neither related to adiposity nor insulin sensitivity. Of interest, a higher mitochondrial ATP production capacity was noted in the men, whereas the women were more insulin sensitive, demonstrating further dissociation between insulin sensitivity and muscle mitochondrial function.
Differential effects of insulin deprivation and systemic insulin treatment on plasma protein synthesis in type 1 diabetic people
Jaleel, Abdul , Klaus, Katherine A. , Morse, Dawn M., Karakelides, Helen, Ward, Lawrence E., Irving, Brian A. , Nair, K. Sreekumaran

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | August 5, 2009 | Volume: 297 | Issue: 4 | Pages: E889-E897

10.1152/ajpendo.00351.2009 | PMID 19654285 Get It

It remains to be determined whether systemic insulin replacement normalizes synthesis rates of different plasma proteins and whether there are differential effects on various plasma proteins. We tested a hypothesis that insulin deprivation differentially affects individual plasma protein synthesis and that systemic insulin treatment may not normalize synthesis of all plasma proteins. We measured synthesis rates of 41 plasma proteins in seven each of type 1 diabetic (T1DM) and nondiabetic participants (ND) using [ ring-13C6]phenylalanine as a tracer. T1DM were studied while on chronic insulin treatment and during 8 h insulin deprivation. Insulin treatment normalized glucose levels, but plasma insulin levels were higher during insulin treatment than during insulin deprivation in T1DM and ND. Individual plasma proteins were purified by affinity chromatography and two-dimensional gel electrophoresis. Only 41 protein gel spots from over 300 were chosen based on their protein homogeneity. Insulin deprivation and hyperglycemia either significantly increased ( n = 12) or decreased ( n = 12) synthesis rates of 24 of 41 plasma proteins in T1DM compared with ND. Insulin treatment normalized synthesis rates of 13 of these 24 proteins, which were altered during insulin deprivation. However, insulin treatment significantly altered the synthesis of 14 additional proteins. In conclusion, acute insulin deprivation caused both a decrease and increase in synthesis rates of many plasma proteins with various functions. Moreover, chronic systemic insulin treatment not only did not normalize synthesis of all plasma proteins but also altered synthesis of several additional proteins that were unaltered during insulin deprivation.
Phenotypic variation in Actinobacillus actionmycetemcomitans during laboratory growth: implications for virulence
Furgang, David, Schreiner, Helen, Goncharoff, P, Charlesworth, Jon E. , Ghazwan, Ghazi, Fitzgerald-Bocarsly, Patricia, Figurski, David H., Fine, Daniel H. , Fitzgerald‐Bocarsly, Patricia

Mayo Clinic

Microbiology | June 5, 2009 | Volume: 145 | Issue: 6 | Pages: 1335-1347

10.1099/13500872-145-6-1335 | PMID 10411260 Get It